Patents Assigned to AstraZeneca
  • Chemical Compounds-149
    Publication number: 20080312206
    Abstract: The invention relates to chemical compounds, or pharmaceutically acceptable salts thereof of the formula which possess CSF 1R kinase inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.
    Type: Application
    Filed: December 19, 2006
    Publication date: December 18, 2008
    Applicant: AstraZeneca AB
    Inventors: Brian Aquila, Donald Cook, Leslie Dakin, Stephanos Ioannidis, Paul Lyne, David Scott, Xiaolan Zheng
  • Pyridine Analogues
    Publication number: 20080312208
    Abstract: The present invention relates to certain new pyridin analogues of Formula (I) Chemical formula should be inserted here. Please see paper copy Formula (I) to processes for preparing such compounds, to their utility as P2Y12 inhibitors and as anti-thrombotic agents etc, their use as medicaments in cardiovascular diseases as well as pharmaceutical compositions containing them.
    Type: Application
    Filed: July 4, 2006
    Publication date: December 18, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Soren Andersen, Peter Bach, Kay Brickmann, Fabrizio Giordanetto, Fredrik Zetterberg, Krister Osterlund
  • Bicyclic Piperazines as Metabotropic Glutatmate Receptor Antagonists
    Publication number: 20080312240
    Abstract: The invention relates to compounds of formula I or pharmaceutically acceptable salts or solvates thereof: where Ar1, A, Hy, R1, m and n are as defined in the description. The invention also includes pharmaceutical compositions and uses of, and processes of making the compounds, as well as methods of medical treatment of mGluR5-mediated disorders.
    Type: Application
    Filed: August 4, 2006
    Publication date: December 18, 2008
    Applicant: AstraZeneca AB
    Inventors: Louise Edwards, Methvin Isaac, Abdelmalik Slassi, Guang-Ri Sun, Tao Xin, Alexander Minidis, Peter Dove
  • PIPERDINE COMPOUNDS AND USES THEREOF-911
    Publication number: 20080312255
    Abstract: Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.
    Type: Application
    Filed: June 11, 2008
    Publication date: December 18, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Gregory Basarab, Pamela Hill, Fei Zhou
  • Antibacterial Pyrrolopyridines, Pyrrolopyrimidines and Pyrroloazepines-154
    Publication number: 20080312211
    Abstract: Compounds of formula (I) and their pharmaceutically acceptable salts are described: formula (I). Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.
    Type: Application
    Filed: December 19, 2006
    Publication date: December 18, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Gregory Basarab, Haihong Ni, Brian Sherer, Fei Zhou
  • Compounds and uses thereof
    Patent number: 7465795
    Abstract: This invention relates to novel compounds having the structural formula I below: and their pharmaceutically acceptable salts, tautomers or in vivo-hydrolysable precursors, compositions and methods of use thereof. These novel compounds provide a treatment or prophylaxis of anxiety disorders, cognitive disorders, and/or mood disorders.
    Type: Grant
    Filed: December 18, 2006
    Date of Patent: December 16, 2008
    Assignee: AstraZeneca AB
    Inventors: Marc J. Chapdelaine, Cyrus J. Ohnmacht, Christopher Becker, Hui-Fang Chang, Bruce T. Dembofsky
  • Derivatives of 4-(imidazol-5-yl)-2-(4-sulfoanilino)pyrimidine with CDK inhibitory activity
    Patent number: 7465728
    Abstract: Compounds of the formula (I): wherein R1, R2, R3, R4, R5 and p are as defined within and a pharmaceutically acceptable salts and in vivo hydrolysable esters are described. Also described are processes for their preparation and their use as medicaments, particularly medicaments for producing a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal, such as man.
    Type: Grant
    Filed: March 6, 2003
    Date of Patent: December 16, 2008
    Assignee: AstraZeneca AB
    Inventors: Nicholas John Newcombe, Andrew Peter Thomas
  • Compounds
    Publication number: 20080306107
    Abstract: The present invention relates to new compounds of formula (I) wherein R1 to R9, X, p and n are defined as in claim 1, or salts, solvates or solvated salts thereof, processes for their preparation and to new intermediates used in the preparation thereof, pharmaceutical compositions containing said compounds and to the use of said compounds in therapy.
    Type: Application
    Filed: December 22, 2005
    Publication date: December 11, 2008
    Applicant: AstraZeneca AB
    Inventors: Andrew Griffin, Andrea Penwell, Miroslaw Tomaszewski, Simon Woo
  • Oxadiazole Derivatives and Their Use as Metabotropic Glutamate Receptor Potentiators 842
    Publication number: 20080306077
    Abstract: Compounds of Formula I: wherein R1 and Q are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.
    Type: Application
    Filed: June 6, 2008
    Publication date: December 11, 2008
    Applicant: AstraZeneca AB
    Inventors: Joshua Clayton, Ian Egle, James Empfield, James Folmer, Methvin Isaac, Fupeng Ma, Abdelmalik Slassi
  • Therapeutic Agents
    Publication number: 20080306087
    Abstract: The present invention relates to compounds of formula (I) and processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, to methods for their therapeutic use and to pharmaceutical compositions containing them.
    Type: Application
    Filed: August 3, 2006
    Publication date: December 11, 2008
    Applicant: ASTRAZENECA AB
    Inventors: James R. Empfield, Michael Laplante, Megan Murphy King, Thomas R. Simpson, Maxime C. Tremblay, James M. Woods, Jingbo Yan
  • Metabotropic Glutamate Receptor Oxadiazole Ligands and Their Use as Potentiators 841
    Publication number: 20080306088
    Abstract: Compounds of Formula I: wherein R1, R2, R3, R4 and Q are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.
    Type: Application
    Filed: June 6, 2008
    Publication date: December 11, 2008
    Applicant: AstraZeneca AB
    Inventors: Joshua Clayton, Ian Egle, James Empfield, James Folmer, Methvin Isaac, Fupeng Ma, Abdelmalik Slassi
  • Alkylnitrile Quinolines as Nk-3 Receptor Ligands
    Publication number: 20080306110
    Abstract: Compounds of Formula I wherein R1, A, R2, R3, R4, R5, n, m and q are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.
    Type: Application
    Filed: September 19, 2006
    Publication date: December 11, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Jeffrey S. Albert, Cristobal Alhambra, James Kang, Gerard M. Koether, Thomas R. Simpson, James Woods, Yan Li
  • Quinazoline Derivatives, Process for Their Preparation and Their Use as Anti-Cancer Agents
    Publication number: 20080306096
    Abstract: The invention relates to chemical compounds of the formula (I) or pharmaceutically acceptable salts thereof, which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.
    Type: Application
    Filed: December 19, 2006
    Publication date: December 11, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Brian Aquila, Jayachandran Ezhuthachan, Paul Lyne, Timothy Pontz, Xiaolan Zheng
  • Heterocyclic Mchr1 Antagonists And Their Use In Therapy
    Publication number: 20080306055
    Abstract: Compounds of formula I depicted below, pharmaceutical compositions containing them, processes for preparing the compounds, and their use in the treatment of obesity, type II diabetes, metabolic syndrome, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy and related conditions, neurological disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea and Alzheimer's disease, and pain related disorders. The compounds are melanin concentrating hormone receptor 1 (MCHr1) antagonists.
    Type: Application
    Filed: December 19, 2005
    Publication date: December 11, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Bryan Egner, Fabrizio Giordanetto, Tord Inghardt
  • Quinazoline derivatives as Src tyrosine kinase inhibitors
    Patent number: 7462623
    Abstract: The invention concerns quinazoline derivatives of Formula (I): (A chemical formula should be inserted here—please see paper copy enclosed herewith) wherein Z is an O, S, SO, SO2, N(R2) or C(R2)2 group wherein each R2 group is hydrogen or (1-8C) alkyl, m is 0, 1, 2 or 3, each R1 group is selected from halogeno, (1-8C) alkyl, (1-6C) alkoxy and any of the other meanings defined in the description, n is 0, 1, 2 or 3, and each R3 group is selected from halogeno, (1-8C) alkyl, (1-6C) alkoxy and any of the other meanings defined in the description, or pharmaceutically-acceptable salts thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumor disease.
    Type: Grant
    Filed: October 29, 2003
    Date of Patent: December 9, 2008
    Assignee: AstraZeneca AB
    Inventor: Patrick Ple
  • Therapeutic agents
    Patent number: 7462644
    Abstract: The present invention provides the S enantiomer of a compound of formula I wherein R1 represents chloro, trifluoromethyl or trifluoromethoxy, R2 represents H or fluoro and R3 represents a C2-4alkyl group as well as pharmaceutically acceptable salts, solvates and prodrugs thereof, to processes for preparing such compounds, to their the utility in treating clinical conditions including lipid disorders (dyslipidemias) whether or not associated with insulin resistance, to methods for their therapeutic use and to pharmaceutical compositions containing them.
    Type: Grant
    Filed: December 19, 2003
    Date of Patent: December 9, 2008
    Assignee: AstraZeneca AB
    Inventors: Eva-Lotte Lindstedt Alstermark, Anna Christina Olsson, Lanna Li, Carl-Johan Aurell, Anna Minidis, Esmail Yousefi-Salakdeh, Mikael Ulf Johan Dahlström
  • Novel Benzothiazolone Derivatives
    Publication number: 20080300275
    Abstract: The present invention provides compounds of formula (I) wherein e, R1, R2, R3, R4, R5, R4, R5, R6, R7, R7a, R7b, A, D, m and n are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: August 3, 2006
    Publication date: December 4, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Roger Bonnert, Alice Flaherty, Garry Pairaudeau, Michael Stocks
  • N-Piperidine Derivatives as Ccr3 Modulators
    Publication number: 20080300232
    Abstract: Compounds of formula I, processes for preparing such compounds, their use in the treatment of obesity, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, and neurological disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea and Alzheimer's disease and pain related disorders and to pharmaceutical compositions containing them.
    Type: Application
    Filed: March 21, 2005
    Publication date: December 4, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Kay Brickmann, Bryan J. Egner, Fabrizio Giordanetto, Tord Inghardt, Anna Linusson Jonsson, Fritiof Ponten
  • NOVEL COMPOUNDS
    Publication number: 20080300244
    Abstract: The present invention provides compounds of formula wherein R1, Y1, X1, Z1, X2, Y2, A, n and R2 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: December 13, 2007
    Publication date: December 4, 2008
    Applicant: AstraZeneca AB
    Inventors: Roger Victor BONNERT, Thomas McInally, Tobias Mochel, Stephen Thom
  • Blister pack device
    Patent number: D582240
    Type: Grant
    Filed: November 12, 2007
    Date of Patent: December 9, 2008
    Assignee: AstraZeneca AB
    Inventors: Maria Benktzon, Anders Löfgren, Sofia Jacobsson, Thomas Nilsson, Ulrika Vejbrink